Paul Liknaitzky is Head of Clinical Psychedelic Research at Monash University, and Chief Principal Investigator on a program of psychedelic trials. He is a Research Fellow within both the Turner Institute and the Dept of Psychiatry at Monash University, and earned an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne. In Australia, he is an Investigator on several of the country’s initial psychedelic trials, has coordinated a number of psychedelic therapist training and supervision programs, obtained the first industry funding for psychedelic science, and leads the first clinical psychedelic lab. His work is focused on developing a rigorous program of research in clinical psychedelics that seeks to evaluate therapeutic effects, innovate on treatment design, mitigate known risks, explore potential drawbacks, and understand therapeutic mechanisms.
